Description

Flucytosine (CAS No. 2022-85-7), also known as 5-Fluorocytosine, is a fluorinated pyrimidine analog with the molecular formula C₄H₄FN₃O. This white to off-white crystalline powder is a potent antifungal agent, widely utilized in microbiological and pharmacological research. Its IUPAC name, 6-amino-5-fluoro-1H-pyrimidin-2-one, reflects its precise chemical structure, featuring a fluorine substitution at the 5-position of the cytosine ring. Flucytosine is highly soluble in water and exhibits stability under standard laboratory conditions, making it ideal for in vitro and in vivo studies. Researchers value its selective toxicity against fungal cells, particularly when investigating synergistic effects with other antifungals like amphotericin B. Our high-purity Flucytosine (>98%) is rigorously tested via HPLC and NMR to ensure consistency, making it a reliable choice for academic, clinical, and industrial applications.

Properties

• CAS Number: 2022-85-7
• Complexity: 208
• IUPAC Name: 6-amino-5-fluoro-1H-pyrimidin-2-one
• InChI: InChI=1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)
• InChI Key: XRECTZIEBJDKEO-UHFFFAOYSA-N
• Exact Mass: 129.03383992
• Molecular Formula: C4H4FN3O
• Molecular Weight: 129.09
• SMILES: C1=NC(=O)NC(=C1F)N
• Topological: 67.5
• Monoisotopic Mass: 129.03383992
• Physical Description: Solid
• Color/Form: White crystalline solid
• Odor: Odorless
• Solubility: >19.4 [ug/mL]
• Stability/Shelf Life: Stable under recommended storage conditions.
• Dissociation Constants: 3.26
• Synonyms: 5-Fluorocytosine, flucytosine, 2022-85-7, Fluorocytosine, Ancotil, 5-Fluorocystosine, Flucytosin, Fluocytosine, 5-Fluorocytosin, Fluorcytosine, 5-FC, Alcobon, Flucytosinum, Flucitosina, Cytosine, 5-fluoro-, Ro 2-9915, 4-Amino-5-fluoropyrimidin-2(1H)-one, 4-Amino-5-fluoro-2(1H)-pyrimidinone, 5-Flucytosine, 2(1H)-Pyrimidinone, 4-amino-5-fluoro-, 2-Hydroxy-4-amino-5-fluoropyrimidine, Ro 29915 E/265601, Flucytosinum [INN-Latin], flucytosina, CHEBI:5100, NSC 103805, Ro-2-9915, HSDB 3082, EINECS 217-968-7, Ro-29915, NSC-103805, DTXSID3023059, UNII-D83282DT06, 2(1H)-Pyrimidinone, 4-amino-5-fluoro-), NSC103805, D83282DT06, DTXCID403059, EC 217-968-7, Flucytosine [USAN:USP:INN:BAN:JAN], Flucytosinum (INN-Latin), FLUCYTOSINE (MART.), FLUCYTOSINE [MART.], FLUCYTOSINE (USP-RS), FLUCYTOSINE [USP-RS], FLUCYTOSINE (EP MONOGRAPH), FLUCYTOSINE (USP IMPURITY), FLUCYTOSINE [EP MONOGRAPH], FLUCYTOSINE [USP IMPURITY], FLUCYTOSINE (USP MONOGRAPH), FLUCYTOSINE [USP MONOGRAPH], Flucytosine (USAN:USP:INN:BAN:JAN), Flucytosinum (Latin), EMTRICITABINE IMPURITY E, D01AE21, J02AX01, 217-968-7, Ancobon, 117969-88-7, 4-amino-5-fluoropyrimidin-2-ol, 5-fluoro cytosine, 5-Flurocytosine, 2-Pyrimidinol, 4-amino-5-fluoro- (9CI), 6-amino-5-fluoro-1H-pyrimidin-2-one, Ancobon (TN), 2(1H)-Pyrimidinone, 6-amino-5-fluoro-, 130256-61-0, Flucytosine (Ancobon), 4-Amino-5-fluoro-2-hydroxypyrimidine, 2-Pyrimidinol, 4-amino-5-fluoro-, MFCD00006035, 6-amino-5-fluoropyrimidin-2(1H)-one, MLS000069463, 2(1H)-Pyrimidinone, 5-fluoro-3,4-dihydro-4-imino- (9CI), 4-amino-5-fluoro-1,2-dihydropyrimidin-2-one, 5-FLUORO-4-IMINO-1,2,3,4-TETRAHYDROPYRIMIDIN-2-ONE, Flucytosine [USAN), 4-Amino-5-fluoro-1H-pyrimidin-2-one, NCGC00016599-01, Flucitosina [DCIT], SMR000059047, ST028644, 6-amino-5-fluoro-3-hydropyrimidin-2-one, CAS-2022-85-7, 4-AMINO-5-FLUORO-2(1H)-PYRIMIDINE, 6-amino-5-fluoro-1,2-dihydropyrimidin-2-one, FLUCYTOSINE [USAN], Flucytosone, Ancotyl, pyrimidine, 4-amino-5-fluoro-2-hydroxy-, 6-Amino-2-oxo-5-fluoropyrimidine, 6-Amino-5-fluoro-2(1H)-pyrimidinone, Flourocytosine, Ancoban, 4-AMINO-2-HYDROXY-5-FLUOROPYRIMIDINE, 5-fluorocytocine, 5-fluoro-cytosine, 4-Amino-5-fluoro-2-hyroxypyrimidine, GL663142 & 5FC, Flucytosine (Standard), CPD000059047, Opera_ID_178, 5-fluorocytosine Form I, FLUCYTOSINE [MI], Prestwick0_000934, Prestwick1_000934, Prestwick2_000934, Prestwick3_000934, FLUCYTOSINE [INN], FLUCYTOSINE [JAN], 5-fluorocytosine Form II, F0321, FLUCYTOSINE [HSDB], 5-Fluorocytosine (5-FC), Flucytosine 100 microg/mL in Acetonitrile:Water, WLN: T6MVNJ DZ EF, CHEMBL1463, SCHEMBL24063, SCHEMBL24064, BSPBio_000868, FLUCYTOSINE [WHO-DD], FLUCYTOSINE [WHO-IP], MLS000759519, MLS001076503, MLS001424013, Flucytosine, 5-Fluorocytosine, SCHEMBL439755, SCHEMBL439756, SPBio_003037, BPBio1_000956, GL663142 & 4-Amino-5-fluoropyrimidin-2(1H)-one, SCHEMBL1223489, SCHEMBL4434518, Flucytosine (JP18/USP/INN), SCHEMBL14696800, HY-B0139R, FLUCYTOSINE [ORANGE BOOK], Flucytosine for system suitability, 4-amino-5-fluoro-pyrimidin-2-ol, GLXC-21527, HMS1570L10, HMS2051M04, HMS2093J05, HMS2097L10, HMS2233I14, HMS3373L05, HMS3393M04, HMS3655G17, HMS3714L10, HMS5079P08, Pharmakon1600-01505429, 5-FLUOROCYTOSINE [WHO-IP], BCP02877, Flucytosine 2.0 mg/ml in Methanol, FLUCYTOSINUM [WHO-IP LATIN], HY-B0139, Tox21_110515, BDBM50248003, NSC759130, s1666, SBB000061, STK292386, AKOS004912683, AKOS005063821, AKOS015896898, AKOS030241326, Tox21_110515_1, BCP9000692, CCG-100837, CCG-213434, CS-1935, DB01099, FF02813, GS-5578, KS-1060, NC00087, NSC-759130, SB57097, Cytosine, 5-fluoro- (6CI,7CI,8CI), NCGC00016599-02, NCGC00016599-04, NCGC00016599-05, AC-11748, BP-30254, EMTRICITABINE IMPURITY E [WHO-IP], NCI60_000093, SY004438, BCP0726000281, DB-005380, DB-268955, DB-271174, AB00513969, NS00000532, SW197278-3, D00323, EN300-117264, H10295, AB00444223-16, AB00513969-02, AB00513969_03, AB00513969_04, 5-Fluorocytosine, Vetec(TM) reagent grade, 99%, Q238490, SR-01000721885, SR-01000721885-5, 4-Amino-5-fluoro-2(1H)-pyrimidine;Flucytosine;5-FC, BRD-K82143716-001-15-7, BRD-K82143716-001-19-9, BRD-K82143716-001-20-7, 4-AMINO-5-FLUOROPYRIMIDIN-2(1H)-ONE [WHO-IP], Z1201621875, Flucytosine, European Pharmacopoeia (EP) Reference Standard, 2(1H)-PYRIMIDINONE, 5-FLUORO-3,4-DIHYDRO-4-IMINO-, Flucytosine, United States Pharmacopeia (USP) Reference Standard, Flucytosine, Pharmaceutical Secondary Standard; Certified Reference Material, Flucytosine for system suitability, European Pharmacopoeia (EP) Reference Standard, 1LD

Application

Flucytosine is primarily used as an antifungal agent in research and clinical settings, targeting infections caused by Candida and Cryptococcus species. It acts by inhibiting fungal RNA and DNA synthesis after conversion to 5-fluorouracil. Studies also explore its role in combination therapies to prevent resistance development. Additionally, Flucytosine serves as a model compound for investigating fluorinated pyrimidine metabolism in microbial systems.

Safety and Hazards

GHS Hazard Statements

• H361: Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

Precautionary Statements

• P203, P280, P318, P405, and P501

Hazard Classes and Categories

• Repr. 2 (83.8%)

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.